20Jun 2022
Baroreflex activation therapy with the barostim™ device in patients with heart failure with reduced ejection fraction: A patient level meta‐analysis of randomized controlled trials

Baroreflex activation therapy with the barostim™ device in patients with heart failure with reduced ejection fraction: A patient level meta‐analysis of randomized controlled trials

HFrEF remains associated with high morbidity and mortality, poor quality of life (QoL) and significant exercise limitation. Analyzed all randomized trial evidence to evaluate the effect of baroreflex activation therapy (BAT) on HF symptoms, QoL and NT‐proBNP in HFrEF. An IPD meta‐analysis suggests that BAT improves exercise capacity and QoL in HFrEF patients receiving GDMT. This clinically meaningful improvement was consistent across trials and in three investigated patient cohorts and was associated with reduced NT‐proBNP in subjects with a lower baseline NT‐proBNP.

  • #cardiology

Like

Save

Share